When SGLT2 med Farxiga scored a major cardiovascular outcomes win last month, AstraZeneca touted the trial results as a game changer for the market. Turns out the FDA likes those results, too—and it’s expediting a review of Farxiga’s CV label
read moreKyprolis looks poised to break the blockbuster barrier, and combo data with multiple myeloma’s hottest drug could help boost it further. Adding J&J’s Darzalex to Kyprolis and dexamethasone cut patients’ risk of disease progression or death by 37%. More: Amgen's
read moreAttendances for the 20% of the population living in the most deprived areas also account for 27% of all A&E attendances. More: A&E attendances twice as high in deprived areas Source: News
read moreThe drug was able to reduce annualised MS relapse rates by 50.5% and 58.5% in the ASCLEPIOS I and II trials. More: Novartis’ MS drug trumps Sanofi’s Aubagio Source: News
read moreThe new collaboration will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring devices from Medtronic. More: Medtronic, Novo Nordisk enter digital diabetes solutions deal Source: News
read moreThe discovery could aid the development of more personalised treatments for myeloma patients. More: ICR discovers major biological processes in myeloma development Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals